Kaveri Pohlman
Stock Analyst at Clear Street
(0.47)
# 4,122
Out of 5,017 analysts
25
Total ratings
25%
Success rate
-25.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTYX Ventyx Biosciences | Initiates: Buy | $11 | $3.56 | +208.99% | 1 | Oct 1, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $24 → $41 | $26.79 | +53.04% | 1 | Sep 30, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $46 | $24.49 | +87.83% | 1 | Sep 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $32 | $20.89 | +53.22% | 1 | Jun 25, 2025 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.69 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $31.81 | +47.75% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $7.40 | +305.41% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $13.03 | +191.63% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $3.74 | +33.69% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $26.51 | +133.87% | 1 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.70 | +116.22% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $38.15 | -29.23% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $14.60 | +379.45% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.84 | +552.17% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $3.36 | +138.10% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $4.41 | +111,646.03% | 2 | Feb 9, 2022 |
Ventyx Biosciences
Oct 1, 2025
Initiates: Buy
Price Target: $11
Current: $3.56
Upside: +208.99%
RAPT Therapeutics
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $41
Current: $26.79
Upside: +53.04%
Oruka Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $24.49
Upside: +87.83%
ArriVent BioPharma
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $20.89
Upside: +53.22%
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.69
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $31.81
Upside: +47.75%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $7.40
Upside: +305.41%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $13.03
Upside: +191.63%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $3.74
Upside: +33.69%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $26.51
Upside: +133.87%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $3.70
Upside: +116.22%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $38.15
Upside: -29.23%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $14.60
Upside: +379.45%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $1.84
Upside: +552.17%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $3.36
Upside: +138.10%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $4.41
Upside: +111,646.03%